NewsRx

Search our medical news database

AIDS Vaccines

Better Understanding of gp120 Immunity Seen as Key to HIV Vaccine

Published in Vaccine Weekly, August 11th, 1997

Understanding the immunology of the HIV-1 gp120 envelope glycoprotein is essential for the development of an AIDS vaccine, argues a team of leading AIDS researchers.

The team, including David D. Ho, Martin Markowitz, and John P. Moore of the Aaron Diamond AIDS Research Center (ADARC), studied HIV antibody responses to HIV-1 Env and Gag antigens in several cohorts of HIV infected individuals.

They found, in agreement with previous studies, that only long-term nonprogressors (LTNP) mount effective anti-gp120 antibody responses. In contrast, most people infected with HIV mount a massive, but almost completely ineffective response to the antigen.

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook